State of the art of immunoassay methods for B-type natriuretic peptides: An update

Critical Reviews in Clinical Laboratory Sciences

Volumn 52, Issue 2, 2015, Pages 56-69

  Clerico, Aldo ^a   Franzini, Maria ^a   Masotti, Silvia ^a   Prontera, Concetta ^a   Passino, Claudio ^a  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Cardiac endocrine function; Cardiovascular risk; Heart failure; Immunoassay methods; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE HORMONE; BIOLOGICAL MARKER;

BIOLOGICAL ACTIVITY; CHROMATOGRAPHY; CROSS REACTION; GLYCOSYLATION; HEART FAILURE; HUMAN; IMMUNOASSAY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; QUALITY CONTROL; REVIEW; BLOOD;

BIOMARKERS; HEART FAILURE; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN;

EID: 84930847524     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2014.987720     Document Type: Review

References (124)

1. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care. Eur Heart J 2012; 33:2001-6.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240-327.
3. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
4. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330: 625.
5. Clerico A, Fontana M, Zyw L, et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813-22.
6. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38: 101-13.
7. Clerico A, Fontana M, Ripoli A, Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009;48:163-79.
8. Richards AM, Troughton EW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012;58:62-71.
9. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013; 127:500-7.
10. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35:16-24.
11. Dickestein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008;10:933-89.
12. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
13. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011;301:H12-20.
14. Goetze JP, Rehfeld JF. Peptide hormones and their prohormones as biomarkers. Biomark Med 2009;3:335-8.
15. Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316: 129-35.
16. Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
17. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
18. Hammerer-Lercher A, Halfinger B, Sarg B, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008;54:858-65.
19. Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51: 486-93.
20. Apple FS, Wu AH, Jaffe AS, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Chem 2007;53:547-51.
21. Goetze JP. Biosynthesis of cardiac natriuretic peptides. Results Probl Cell Differ 2010;50:97-120.
22. Schellenberger U, O'Rear J, Guzzetta A, et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
23. Seferian KR, Tamm NN, Semenov AG, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866-73.
24. Crimmins DL, Kao JL. A glycosylated form of the human cardiac hormone pro B-type natriuretic peptide is an intrinsically unstructured monomeric protein. Arch Biochem Biophys 2008; 475:36-41.
25. Semenov AG, Postnikov AB, Tamm NN, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009;55: 489-98.
26. Tonne JM, Campbell JM, Cataliotti A, et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardio-myocytes. Clin Chem 2011;57:864-73.
27. Semenov AG, Tamm NN, Seferian KR, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010;56:1166-76.
28. Ichiki T, Huntley BK, Burnett JC Jr. BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem 2013;61:1-31.
29. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-7.
30. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Desserine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007;292:R897-901.
31. Vanderheyden M, Bartunek J, Goethals M, et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009;47:248-52.
32. Pankow K, Wang Y, Gembardt F, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007;101:875-82.
33. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am J Physiol Regul Integr Comp Physiol 2009;296: R1744-50.
34. Toll L, Brandt SR, Olsen CM, et al. Isolation and characterization of a new atrial peptide-degrading enzyme from bovine kidney. Biochem Biophys Res Commun 1991;175:886-93.
35. Muller D, Schulze C, Baumeister H, et al. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 1992;31:11138-43.
36. Ralat LA, Guo Q, Ren M, et al. Insulin degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem 2011;286:4670-9.
37. Belenky A, Smith A, Zhang B, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004;340: 163-72.
38. Hawkridge AM, Heublein DM, Bergen III HR , et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005;102:17442-7.
39. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:335-60.
40. Nishikimi T, Ikeda M, Takeda Y, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012;98:152-61.
41. Nishikimi T, Kuwahara K, Nakagawa Y, et al. Complexity of molecular forms of B-type natriuretic peptide in heart failure. Heart 2013;99:677-9.
42. Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054-61.
43. Dong N, Chen S, Yang J, et al. Plasma soluble corin in patients with heart failure. Circ Heart Fail 2010;3:207-11.
44. Ichiki T, Huntley BK, Heublein DM, et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natri-uretic peptide processing in the circulation. Clin Chem 2011;57: 40-7.
45. Knappe S, Wu F, Masikat MR, et al. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem 2003; 278:52363-70.
46. Semenov AG, Seferian KR, Tamm NN, et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem 2011;57:883-90.
47. Clerico A, Vittorini S, Passino C. Measurement of the prohormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011;49:1949-54.
48. Clerico A, Vittorini S, Passino C. Circulating forms of the B-type natriuretic peptide prohormone: pathophysiologic and clinical considerations. Adv Clin Chem 2012;58:31-44.
49. Dong N, Chen S, Wang W, et al. Corin in clinical laboratory diagnostics. Clin Chim Acta 2012;413:378-83.
50. Del Ry S, Cabiati M, Clerico A. Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure. Pharmacol Res 2013;76:190-8.
51. Emdin E, Clerico A, Clemenza F, et al. Consensus document. Recommendations for the clinical use of cardiac natriuretic peptides. J Cardiovasc Med 2005;6:430-46.
52. Clerico A, Del Ry S, Giannessi D. Measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46:1529-34.
53. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50.
54. Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619-21.
55. Emdin M, Passino C, Clerico A. Natriuretic peptide assays revisited: do we need pro-B-type natriuretic peptide? J Am Coll Cardiol 2011;57:1396-8.
56. Prontera C, Zaninotto M, Giovannini S, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmoCheck study. Clin Chem Lab Med 2009;47:762-8.
57. Clerico A, Zaninotto M, Prontera C, et al. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim Acta 2012;414:112-19.
58. Apple FS. B-type natriuretic peptides. Analytical and clinical considerations. Clin Lab News 2005;31:12-4.
59. Analytical characteristics of commercial MR-proANP, BNP and NT-proBNP Assays as per the manufacturer. IFCC document. Available at: http://www.ifcc.org/media/102208/NP%20Assay %20Table%20C%20SMCD%20vJuly-2011.pdf [last accessed 21 Oct 2014].
60. Franzini M, Masotti S, Prontera C, et al. Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials. Clin Chim Acta 2013;424:287-91.
61. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439-45.
62. Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides.Clin ChimActa2014 Jun 14.pii: S0009-8981(14)00261-7. doi: 10.1016/j.cca.2014.06.003. [Epub ahead of print].
63. Panteghini M, Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 2004;50:325-31.
64. Storti S, Prontera C, Emdin M, et al. Analytical performance and clinical results of a fully automated MEIA system for BNP assay: comparison with a POCT method. Clin Chem Lab Med 2004;42: 1178-85.
65. Clerico A, Prontera C, Emdin M, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 2005;51:445-7.
66. Prontera C, Storti S, Emdin M, et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Chem 2005;51:1274-6.
67. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
68. Tamm NN, Seferian KR, Semenov AG, et al. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clin Chem 2008;54:1511-18.
69. Wu AH, Smith A, Rame E, et al. Analytical assay characterization for 1-108 pro-B-type natriuretic peptide on the BioPlex 2200 analyzer. Clin Chim Acta 2009;408:143-4.
70. Macheret F, Boerrigter G, McKie P, et al. Pro-B-type natriuretic peptide 1-108 circulates in the general community: plasma determinants and detection of left ventricular systolic dysfunction. J Am Coll Cardiol 2011;57:1386-95.
71. Miller WL, Burnett JC Jr, Hartman KA, et al. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin Chim Acta 2009;406:119-23.
72. Bargnoux AS, Klouche K, Fareh J, et al. Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafil-tration. Clin Chem Lab Med 2008;46:1019-24.
73. Iervasi G, Clerico A, Berti S, et al. Altered tissue degradation and distribution of atrial natriuretic peptide in patients with idio-pathic dilated cardiomyopathy and its relationship with clinical severity of the disease and sodium handling. Circulation 1995;91: 2018-27.
74. Clerico A, Iervasi G. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? J Card Fail 1995;1:323-8.
75. Clerico A, Emdin M. Endocrine paradox in heart failure: resistance to biological effects of cardiac natriuretic hormones. Clin Chem 2004;50:2465-7.
76. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;9:1503-10.
77. Niederkofler EE, Kiernan UA, O'Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1: 258-64.
78. Dickey DM, Potter LR. ProBNP1-108 is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin Chem 2011;57:1272-8.
79. Dries DL, Ky B, Wu AH, et al. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ Heart Fail 2010;3:220-7.
80. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.
81. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
82. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4.
83. Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004;50:867-73.
84. Sykes E, Karcher RE, Eisenstadt J, et al. Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. Am J Clin Pathol 2005;123:584-90.
85. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta 2006;369:95-9.
86. Naik GO, Moe GW. Use of a solid-phase extraction with radioimmunoassay to identify the proportional bias of clinical B-type natriuretic peptide immunoassay: the impact of plasma matrix and antibody multispecificity. Clin Chem Lab Med 2007; 45:1353-9.
87. Mongia SK, La'ulu SL, Apple FS, et al. Performance characteristics of the Architect brain natriuretic peptide (BNP) assay: a two site study. Clin Chim Acta 2008;391:102-5.
88. Feola M, Valeri L, Menditto E, et al. Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure. J Endocrinol Invest 2010;33:554-8.
89. Shah K, Terracciano GJ, Jiang K, et al. Comparability of results between point-of-care and automated instruments to measure B-type natriuretic peptide. West J Emerg Med 2010;11:44-8.
90. Clerico A, Del Ry S, Maffei S, et al. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40:371-7.
91. Cantinotti M, Clerico A, Murzi M, et al. Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. Clin Chim Acta 2008; 390:12-22.
92. Cantinotti M, Law Y, Vittorini S, et al. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update. Heart Fail Rev 2014;19:727-42.
93. Clerico A, Fontana M, Vittorini S, Emdin M. The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. Clin Chim Acta 2009;405:1-7.
94. Nir A, Nasser N. Value of NT-proBNP and BNP in pediatric cardiology. J Card Fail 2005;11:S76-80.
95. Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8.
96. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 2002;7:29-49.
97. Oxenham H, Sharpe N. Cardiovascular aging and heart failure. Eur J Heart Fail 2003;5:427-34.
98. Clerico A, Passino C, Emdin M. When gonads talk to the heart. J Am Coll Cardiol 2012;58:627-8.
99. Giannessi D, Andreassi MG, Del Ry S, et al. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 2001;24:8-16.
100. Chronic heart failure: National clinical guideline for diagnosis and management in primary and secondary care. NICE Guideline CG108. August 2010;1-222. Available at https://www.nice. org.uk/guidance/cg108 [last accessed 27 Nov 2014].
101. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
102. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33.
103. Di Serio F, Ruggieri V, Varraso L, et al. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005;43:1263-73.
104. Prontera C, Zucchelli CG, Vittorini S, et al. Comparison between analytical performances of polyclonal and monoclonal electro-chemiluminescence immunoassays for NT-proBNP. Clin Chim Acta 2009;400:70-3.
105. Hess G, Runkel S, Zdunek D, Hitzler WE. Reference interval determination for NT-proBNP: a study in blood donors. Clin Chim Acta 2005;360:187-93.
106. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006;44:366-78.
107. Fokkema MR, Herrmann Z, Muskiet FAJ, Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602-3.
108. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
109. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
110. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004;6: 301-8.
111. Luchner A, Hengstenberg C, Löwel H, et al. NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail 2005;11:S21-7.
112. Wu AHB, Smith A. Biological variation of the natriuretic peptides and monitoring patients with heart failure. Eur J Heart Fail 2004; 6:355-8.
113. Bruins S, Fokkema MR, Romer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
114. Klersy C1, d'Eril GV, Barassi A, et al. Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. Clin Chim Acta 2012;413:544-7.
115. Mair J, Falkensammer G, Polzl G, et al. BNP is more sensitive to rapid hemodynamic changes in acute heart failure than NT-proBNP. Clin Chim Acta 2007;379:163-6.
116. Araújo JP, Azevedo A, Lourenço P, et al. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol 2006;98: 1248-50.
117. Jungbauer CG, Kaess B, Buchner S, et al. Equal performance of novel N-terminal proBNP (Cardiac proBNP®) and established BNP (Triage BNP®) point-of-care tests. Biomark Med 2012;6: 789-96.
118. Zaninotto M, Mion MM, Di Serio F, et al. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med 2010;48:1029-34.
119. Christenson ES, Collinson PO, Defilippi CR, Christenson RH. Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Rev Mol Diagn 2014;14:185-97.
120. Maisel A, Barnard D, Jaski B, et al. Primary results of the HABIT Trial (Heart failure assessment with BNP in the home). J Am Coll Cardiol 2013;61:1726-35.
121. Prontera C, Masotti S, Franzini M, et al. Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clin Chem Lab Med 2014 Nov 5. pii:/j/cclm.ahead-of-print/cclm-2014-0873/cclm-2014-0873.xml. doi: 10.1515/cclm-2014-0873
122. Price PC, Christensen RH. Evidence-based Laboratory Medicine: Principles, Practice, and Outcome. 2nd ed. Washington DC: AACC Press, 2007:1-545.
123. Marshall DA, O'Brien BJ. Economic evaluation of diagnostic tests. In: Price PC, Christensen RH, eds. Evidence-based Laboratory Medicine-From Principles to Outcomes. Washington DC: AACC Press, 2003:159-86.
124. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123:551-65.